Key statistics
On Tuesday, Ascentage Pharma Group International (36X:STU) closed at 4.96, 27.18% above the 52 week low of 3.90 set on Apr 08, 2025.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
| Open | 5.00 |
|---|---|
| High | 5.00 |
| Low | 4.84 |
| Bid | 4.96 |
| Offer | 5.20 |
| Previous close | 4.86 |
| Average volume | 0.00 |
|---|---|
| Shares outstanding | 373.32m |
| Free float | 272.60m |
| P/E (TTM) | -- |
| Market cap | 17.28bn HKD |
| EPS (TTM) | -4.00 HKD |
Data delayed at least 15 minutes, as of Feb 10 2026.
More ▼
Announcements
- Ascentage Pharma Announces IND Clearance by the U.S. Food and Drug Administration for BTK Degrader APG-3288
- Ascentage Pharma Appoints Dr. Veet Misra as Chief Financial Officer and Eric Huang as Senior Vice President of Global Corporate Development and Finance
- Live from ASCO 2025 | Ascentage Pharma Releases Promising Clinical Data on Alrizomadlin Monotherapy and Combinations in Solid Tumors
- Live from ASCO 2025 | Ascentage Pharma Presents Clinical Data on Bcl-2 Inhibitor Lisaftoclax in Venetoclax-Refractory Patients in Oral Report
- Ascentage Pharma Announces Clinical Data of Lisaftoclax, Which Shows Therapeutic Potential in Venetoclax-Refractory Patients, Selected for Oral Report at ASCO 2025
- Ascentage Pharma Presents Results from Five Preclinical Studies at 2025 American Association of Cancer Research (AACR) Annual Meeting, Highlighting Strong Synergistic Effects of Olverembatinib Combined with Lisaftoclax
- Ascentage Pharma To Present Data from Two Clinical Studies at 2025 ASCO Annual Meeting, Including Oral Presentation on Its Key Assets Lisaftoclax and Alrizomadlin
- Ascentage Pharma Announces Inclusion of Lisaftoclax and Olverembatinib in Chinese Society of Clinical Oncology (CSCO) 2025 Guidelines
- Ascentage Pharma Reports Full Year 2024 Unaudited Financial Results and Business Updates
- Ascentage Pharma to Present Five Preclinical Studies from Innovative Pipeline at American Association of Cancer Research (AACR) Annual Meeting 2025
More ▼
